Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
The duration of the extension study per participants was 40 weeks broken down as follows:
* 24-week double-blind treatment period,
* 16-week post-treatment elimination follow-up period.
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
PDY6045 or PDY6046 participant who:
* completed the week 24 visit of either study PDY6045 or PDY6046,
* was still meeting eligibility criteria for receiving treatment,
* had agreed to continue stable dose of Interferon-β \[IFN-β\] or Glatiramer Acetate \[GA\] and consented to continue on treatment.
You may not be if
Any known condition or circumstance that would have prevented in the investigator's opinion, compliance or completion of the study
The above information is not intended to contain all considerations relevant to patient's potential participation in a clinical trial.
Clareo Health | Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis
